Andrew Gengos

Neuraltus Pharmaceuticals, Inc. develops and commercializes molecule therapeutics. It engages in the development of therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease as well as inherited metaboloic disorders such as Fabry's disease and Gaucher's disease which also result in neuronal cell death. The company was founded by Michael McGrath, Edgar G. Engleman, and Ari Azhir in 2004 and is headquartered in San Bruno, CA.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

Turn Therapeutics(TM), Inc is a pharmaceutical and medical device organization that aims to reduce the human and economic costs of infection and skin disease. Turn Therapeutics(TM is based in Calabasas, CA. The private company's core mission is to innovate and educate in order to render disease obsolete. The company has multiple, mass market-ready, proprietary assets incorporating advanced delivery and healing technologies, including their FDA cleared product, Hexagen® wound dressing, which is non-irritating, non-cytotoxic, and non-sensitizing, as well as suitable for extended-wear. The company was founded by Bradley Burnam, who has been the CEO since incorporation.